Ligand id: 4919

Name: eritoran

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 21
Hydrogen bond donors 7
Rotatable bonds 61
Topological polar surface area 313.25
Molecular weight 1312.84
XLogP 16.43
No. Lipinski's rules broken 4

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Phase II clinical trial results were reported by Tidswell et al. (2010) [3]. Despite these positive findings eritoran failed to show significant benefit in a subsequent Phase III trial.
Note that the clinically used formulation is eritoran tetrasodium, represented by PubChem CID 6450173.